Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Karyopharm Therapeutics (Nasdaq: KPTI) granted an aggregate of 1,799 restricted stock units (RSUs) to four newly hired employees, effective January 31, 2026, under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

Each RSU vests over three years with 33 1/3% vesting on each anniversary, conditioned on continued service through each vesting date.

Argus Feb 3 session

+3.80% close to close Open Argus

Details

News Market Reaction – KPTI

On Feb 3, the first trading day after this news, KPTI closed 3.80% above the previous close.

Data tracked by StockTitan Argus for the Feb 3 session.

Market Context

This announcement details a routine equity compensation action: 1,799 RSUs granted to four new hires...

Analysis

This announcement details a routine equity compensation action: 1,799 RSUs granted to four new hires under the 2022 Inducement Stock Incentive Plan, vesting over three years at 33 1/3% annually. Prior months featured similar inducement grants plus more material updates on revenue outlook, financing and resale registrations. Investors evaluating this news alongside earlier filings may focus more on liquidity, debt obligations and upcoming clinical and revenue milestones than on today’s modest dilution from employee awards.

Key Figures

Inducement RSUs granted: 1,799 RSUs Number of new employees: 4 employees Vesting period: 3 years +5 more

Inducement RSUs granted

1,799 RSUs

Aggregate awards to four new hires as of Jan 31, 2026

Number of new employees

4 employees

Recipients of inducement RSU grants

Vesting period

3 years

RSUs vest over three consecutive anniversaries of Grant Date

Annual vesting rate

33 1/3%

Portion of RSU grant vesting on each anniversary

Grant Date

January 31, 2026

Effective date for the RSU inducement awards

Resale registration shares

2,805,688 shares

Common stock registered for resale under S-3 dated Nov 3, 2025

Beneficial ownership stake

8.6%

Affinity Asset Advisors and Michael Cho as of Jan 22, 2026

Shares outstanding reference

19,883,800 shares

Shares used to calculate 13G/A ownership percentages

Historical Context

5 past events · Latest: Jan 12

5 events

1. Jan 12

   Prelim. 2025 results

   24h Move

   -5.6%

   Preliminary 2025 revenue outlook and 2026 Phase 3 data timing.

2. Jan 02

   Inducement RSU grants

   24h Move

   +2.9%

   RSU inducement awards to two new hires under 2022 plan.

3. Dec 08

   Conference participation

   24h Move

   +2.4%

   Virtual fireside chat in Baird’s Biotech Discovery Series.

4. Dec 01

   Options and RSU grants

   24h Move

   -6.8%

   Stock options and RSUs as inducement awards for new hires.

5. Dec 01

   Conference appearance

   24h Move

   +2.3%

   Participation in Piper Sandler healthcare conference fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock units (rsus), nasdaq listing rule 5635(c)(4), inducement stock incentive plan

3 terms

restricted stock units (rsus) financial

"granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

nasdaq listing rule 5635(c)(4) regulatory

"as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement stock incentive plan financial

"pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements"

An inducement stock incentive plan is a program that gives newly hired employees or executives shares or stock-based awards as a reward for joining a company and to encourage them to stay and perform. For investors, it matters because these grants can dilute existing shareholders, increase reported compensation costs, and signal how a company is investing in talent—similar to a signing bonus mixed with a stake in the business.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEWTON, Mass., Feb. 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,799 restricted stock units (RSUs) to four newly-hired employees. These RSU awards were granted as of January 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).

Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of each RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and first-in-class, oral exportin 1 (XPO1) inhibitor, XPOVIO^® (selinexor), is approved in the U.S. and marketed by the Company in three oncology indications. It has also received regulatory approvals in various indications in more than 50 ex-U.S. territories and countries, including the European Union, the United Kingdom (as NEXPOVIO^®) and China. Karyopharm has a focused pipeline targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit www.karyopharm.com, and follow us on LinkedIn and on X at @Karyopharm.

XPOVIO^® and NEXPOVIO^® are registered trademarks of Karyopharm Therapeutics Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302673225.html

SOURCE Karyopharm Therapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Karyopharm (KPTI) announce about inducement RSU grants on February 2, 2026?

Karyopharm granted 1,799 RSUs to four new hires effective January 31, 2026. According to the company, the awards were made under its 2022 Inducement Stock Incentive Plan as inducements under Nasdaq Listing Rule 5635(c)(4).

How do the 1,799 RSUs granted by KPTI vest and when do they begin vesting?

The RSUs vest over three years with 33 1/3% vesting on each anniversary. According to the company, the Grant Date was January 31, 2026, and vesting depends on continued service through each anniversary.

Who received the RSU awards from Karyopharm (KPTI) and under what plan were they granted?

Four newly hired employees received the RSU awards as inducements to join the company. According to the company, grants were made under the 2022 Inducement Stock Incentive Plan, as amended, pursuant to Nasdaq rule 5635(c)(4).

Do Karyopharm's (KPTI) RSU awards include performance conditions or only service-based vesting?

The RSU awards are service-based and vest based on continued employment or service through each vesting date. According to the company, vesting is explicitly conditioned on continued service, not on additional performance metrics.

What is the significance of Nasdaq Listing Rule 5635(c)(4) for KPTI's RSU grants?

Rule 5635(c)(4) permits equity inducements for new hires outside prior shareholder-approved plans. According to the company, the RSU awards were granted specifically as inducements in accordance with Nasdaq Listing Rule 5635(c)(4).